Kidney cancer patient summit on immunotherapy/TKI combinations
The following presentations from the Educated Patient® Kidney Cancer Summit [...]
Outcomes of patients who stopped immunotherapy due to immune-related side effects
Immunotherapy has changed the way advanced renal cell carcinoma (RCC) [...]
Risks and benefits of adjuvant therapy for kidney cancer
Treatment of people with intermediate to high risk renal cell [...]
Real world incidence of immune-related side effects to ipilimumab/nivolumab in kidney cancer patients
A recent study published in Journal of Clinical Medicine this [...]
Cabozantinib in combination with atezolizumab for advanced kidney cancer
This phase Ib study reports the results of a combination [...]
Lenvatinib plus pembrolizumab in for untreated and previously treated metastatic kidney cancer
Results from a phase Ib/II study looking at lenvatinib plus [...]
ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer
In a small phase 2 study presented at the virtual [...]
Checkpoint inhibitor re-challenge after immune-related adverse events
Immunotherapy has revolutionised treatment in many cancers, including renal cell [...]
Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer
In this phase 1b/2 study the researchers looked at a [...]
Immune-related adverse events from cabozantinib plus atezolizumab as first-line treatment for advanced kidney cancer
The COSMIC-021 clinical trial investigated a combination of cabozantinib and [...]
